Molecular subtyping reveals luminal bladder tumors have lower rates of pathological upstaging at radical cystectomy
Lotan Y. 1,
Boorjian S.A. 2,
Zhang J. 3,
Bivalacqua T.J. 4,
Porten S.P. 5,
Lerner S.P. 6,
Wheeler T.M. 7,
Hutchinson R. 1,
Francis F. 8,
Du Plessis M. 3,
Davicioni E. 12,
Svatek R. 10,
Black P. 11,
Gibb E.A. 9
1
University of Texas Southwestern Medical Center, Dept. of Urology, Dallas, United States of America 2
Mayo Clinic, Dept. of Urology, Rochester, United States of America 3
GenomeDx Inc., Clinical Development, Vancouver, Canada 4
John Hopkins Medical Institute, Dept. of Urology, Baltimore, United States of America 5
University of California San Francisco, Dept. of Urology, San Francisco, United States of America 6
Baylor College of Medicine Medical Center, Dept. of Urology, Houston, United States of America 7
Baylor College of Medicine Medical Center, Dept. of Pathology and Immunology, Houston, United States of America 8
University of Texas Southwestern Medical Center, Dept. of Pathology, Dallas, United States of America 9
GenomeDX, R&D, San Diego, United States of America 10
University of Texas Health San Antonio, Dept. of Urology, San Antonio, United States of America 11
University of British Columbia, Dept. of Urological Sciences, Vancouver, Canada 12
GenomeDx Inc., R&D, Vancouver, Canada
